<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Problems of Virology</journal-id><journal-title-group><journal-title xml:lang="en">Problems of Virology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы вирусологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0507-4088</issn><issn publication-format="electronic">2411-2097</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16799</article-id><article-id pub-id-type="doi">10.36233/0507-4088-343</article-id><article-id pub-id-type="edn">kdhajd</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Influenza virus infection affects the efficacy of the treatment of dyslipidemia in mice with a polyisoprenoid-based drug</article-title><trans-title-group xml:lang="ru"><trans-title>Гриппозная инфекция затрудняет лечение дислипидемии у мышей препаратом на основе полиизопреноидов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7062-958X</contrib-id><name-alternatives><name xml:lang="en"><surname>Makiev</surname><given-names>Evgeny A.</given-names></name><name xml:lang="ru"><surname>Макиев</surname><given-names>Евгений Алмазович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD Student, Junior Researcher, Laboratory of Cellular Immunity</p></bio><bio xml:lang="ru"><p>аспирант, младший научный сотрудник лаборатории клеточного иммунитета</p></bio><email>makiev31121994@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0507-1935</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozhevnikova</surname><given-names>Tatyana N.</given-names></name><name xml:lang="ru"><surname>Кожевникова</surname><given-names>Татьяна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Researcher, Laboratory of Cellular Immunity</p></bio><bio xml:lang="ru"><p>канд. мед. наук, научный сотрудник лаборатории клеточного иммунитета</p></bio><email>tatiana140663@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5266-9783</contrib-id><name-alternatives><name xml:lang="en"><surname>Pronin</surname><given-names>Alexander V.</given-names></name><name xml:lang="ru"><surname>Пронин</surname><given-names>Александр Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc, Professor, Deputy Director for Research</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор, заместитель директора по научной работе</p></bio><email>proninalexander@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0601-7148</contrib-id><name-alternatives><name xml:lang="en"><surname>Narovlyansky</surname><given-names>Alexander N.</given-names></name><name xml:lang="ru"><surname>Наровлянский</surname><given-names>Александр Наумович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc, Professor, Chief Researcher, Laboratory of Cytokines</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор, главный научный сотрудник лаборатории цитокинов</p></bio><email>narovl@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3091-5802</contrib-id><name-alternatives><name xml:lang="en"><surname>Sanin</surname><given-names>Alexander V.</given-names></name><name xml:lang="ru"><surname>Санин</surname><given-names>Александр Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc, Professor, Head of Laboratory of Cellular Immunity</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор, заведующий лабораторией клеточного иммунитета</p></bio><email>saninalex@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4049-7907</contrib-id><name-alternatives><name xml:lang="en"><surname>Ganshina</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Ганшина</surname><given-names>Ирина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher, Laboratory of Cellular Immunity</p></bio><bio xml:lang="ru"><p>научный сотрудник лаборатории клеточного иммунитета</p></bio><email>ganshina.iren@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5268-1296</contrib-id><name-alternatives><name xml:lang="en"><surname>Shmarov</surname><given-names>Maxim M.</given-names></name><name xml:lang="ru"><surname>Шмаров</surname><given-names>Максим Михайлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc, Head of Laboratory of Molecular Biotechnology</p></bio><bio xml:lang="ru"><p>д-р биол. наук, заведующий лабораторией молекулярной биотехнологии</p></bio><email>mmshmarov@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-05-08" publication-format="electronic"><day>08</day><month>05</month><year>2026</year></pub-date><volume>71</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>139</fpage><lpage>149</lpage><history><date date-type="received" iso-8601-date="2025-08-26"><day>26</day><month>08</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Makiev E.A., Kozhevnikova T.N., Pronin A.V., Narovlyansky A.N., Sanin A.V., Ganshina I.V., Shmarov M.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Макиев Е.А., Кожевникова Т.Н., Пронин А.В., Наровлянский А.Н., Санин А.В., Ганшина И.В., Шмаров М.М.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Makiev E.A., Kozhevnikova T.N., Pronin A.V., Narovlyansky A.N., Sanin A.V., Ganshina I.V., Shmarov M.M.</copyright-holder><copyright-holder xml:lang="ru">Макиев Е.А., Кожевникова Т.Н., Пронин А.В., Наровлянский А.Н., Санин А.В., Ганшина И.В., Шмаров М.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://virusjour.crie.ru/jour/article/view/16799">https://virusjour.crie.ru/jour/article/view/16799</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> To evaluate how influenza infection affects the hypolipidemic effect of a novel combined drug – Prenophytol based on polyisoprenoids (sodium polyprenyl phosphate and beta-sitosterol) in mice with experimental dyslipidemia.</p> <p><bold>Materials and methods. </bold>In BALB/c mice with experimentally induced dyslipidemia, the impact of Prenophytol on lipid metabolism parameters was assessed. Currently the drug is at the stage of clinical trials (Roszdravnadzor's permission to conduct clinical trials No. 362 dated 08/14/2025). A subset of animals was infected with influenza A/California/07/2009 (H1N1) virus.</p> <p><bold>Results.</bold> Administration of the drug to dyslipidemia mice resulted in a significant reduction in total cholesterol, triglycerides, and LDL levels, along with a significant increase in HDL. However, in the presence of influenza infection, the hypolipidemic effect of Prenophytol was markedly attenuated: only cholesterol levels decreased significantly, whereas changes in triglycerides, LDL, and HDL did not reach statistical significance.</p> <p><bold>Conclusions.</bold> Influenza infection diminishes the therapeutic efficacy of the Prenophytol in the treatment of dyslipidemia. These findings indicate that concomitant viral infections must be taken into account when designing dyslipidemia treatment regimens and conducting clinical trials of this drug.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Оценить влияние гриппозной инфекции на гиполипидемический эффект Пренофитола – нового комбинированного препарата на основе полиизопреноидов (полипренилфосфата натрия и β-ситостерина) у мышей с экспериментальной дислипидемией.</p> <p><bold>Материалы и методы.</bold> У мышей BALB/c с экспериментальной дислипидемией исследовали влияние Пренофитола (в настоящее время находится на этапе клинических исследований, разрешение Росздравнадзора на проведение клинических исследований №362 от 14.08.2025) на показатели липидного обмена. Часть животных была инфицирована вирусом гриппа A/California/07/2009 (H1N1).</p> <p><bold>Результаты.</bold> Введение Пренофитола мышам с дислипидемией привело к достоверному снижению уровней общего холестерина, триглицеридов и ЛПНП, а также к повышению ЛПВП. Однако на фоне гриппозной инфекции гиполипидемический эффект Пренофитола был существенно ослаблен: достоверно снижался только уровень холестерина, в то время как динамика триглицеридов, ЛПНП и ЛПВП не достигала статистической значимости.</p> <p><bold>Выводы. </bold>Гриппозная инфекция ослабляет терапевтическую эффективность Пренофитола при лечении дислипидемии. Полученные данные указывают на необходимость учета сопутствующей вирусной инфекции при разработке схем лечения дислипидемии и проведении его клинических испытаний.</p></trans-abstract><kwd-group xml:lang="en"><kwd>dyslipidemia</kwd><kwd>influenza virus</kwd><kwd>viral infection</kwd><kwd>polyisoprenoids</kwd><kwd>Prenophytol</kwd><kwd>sodium polyprenyl phosphate</kwd><kwd>beta-sitosterol</kwd><kwd>poloxamer 407</kwd><kwd>hypolipidemic therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дислипидемия</kwd><kwd>вирус гриппа</kwd><kwd>вирусная инфекция</kwd><kwd>Пренофитол</kwd><kwd>полиизопреноиды</kwd><kwd>полипренилфосфат натрия</kwd><kwd>бета-ситостерин</kwd><kwd>полоксамер 407</kwd><kwd>гиполипидемическая терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>INTERHEART: A Global Case-Control Study of Risk Factors for Acute Myocardial Infarction. Available at: https://medscape.com/viewarticle/489738#vp_2</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kalashnikova M.F. Metabolic syndrome: a modern view on concept, prevention methods and treatment. Effektivnaya farmakoterapiya. 2013; (55): 52–63. https://elibrary.ru/sxmwzt (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Калашникова М.Ф. Метаболический синдром: современный взгляд на концепцию, методы профилактики и лечения. Эффективная фармакотерапия. 2013; (55): 52–63. https://elibrary.ru/sxmwzt</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Kumari R., Kumar S., Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab. Syndr. 2019; 13(4): 2409–17. https://doi.org/10.1016/j.dsx.2019.06.005</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Vona R., Gambardella L., Cittadini C., Straface E., Pietraforte D. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxid. Med. Cell. Longev. 2019; 2019; 8267234. https://doi.org/10.1155/2019/8267234</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zhou Y., Pu J., Wu Y. The role of lipid metabolism in influenza A virus infection. Pathogens. 2021; 10(3): 303. https://doi.org/10.3390/pathogens10030303</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Montone R.A., Camilli M., Calvieri C., Magnani G., Bonanni A., Bhatt D.L., et al. Exposome in ischaemic heart disease: beyond traditional risk factors. Eur. Heart J. 2024; 45(6): 419–38. https://doi.org/10.1093/eurheartj/ehae001</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Haidari M., Wyde P.R., Litovsky S., Vela D., Ali M., Cassels S.W., et al. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis. 2010; 208(1): 90–6. https://doi.org/10.1016/j.atherosclerosis.2009.07.028</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fatkhullina A.R., Peshkova I.O., Koltsova E.K. The role of cytokines in the development of atherosclerosis. Boichemistry (Mosc.). 2016; 81(11): 1358–70. https://doi.org/10.1134/s0006297916110134</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Chen L., Hao G. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. Cardiovasc. Res. 2020; 116(12): 1932–6. https://doi.org/10.1093/cvr/cvaa093</mixed-citation><mixed-citation xml:lang="ru">Chen L., Hao G. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza virusesand cardiovascular disease. Cardiovasc. Res. 2020; 116(12): 1932–6. https://doi.org/10.1093/cvr/cvaa093</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Peretz A., Azrad M., Blum A. Influenza virus and atherosclerosis. QJM. 2019; 112(10): 749–55. https://doi.org/10.1093/qjmed/hcy305</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Nguen J.L., Yang W., Ito K., Matte T.D., Shaman J., Kinney P.L. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016; 1(3): 274–81. https://doi.org/10.1001/jamacardio.2016.0433</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Andrade F.B., Gualberto A., Rezende C., Percegoni N., Gameiro J., Hottz E.D. The weight of obesity in immunity from influenza to COVID-19. Front. Cell. Infect. Microbiol. 2021; 11: 638852. https://doi.org/10.3389/fcimb.2021.638852</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pronin A.V., Danilov L.L., Narovlyansky A.N., Sanin A.V. Plant polyisoprenoids and control of cholesterol level. Arch. Immunol. Ther. Exp. (Warsz). 2014; 62(1): 31–9. https://doi.org/10.1007/s00005-013-0253-y</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Sanin A.V., Pronin A.V., Narovlyansky A.N., Ozherelkov S.V., Sedov A.M. Phosphorilated polyprenols as universal agents of viral reproduction suppression. Biol. Bull. Rev. 2022; 12(6): 609–24. https://doi.org/10.1134/S207908642206007X</mixed-citation><mixed-citation xml:lang="ru">Sanin A.V., Pronin A.V., Narovlyansky A.N., Ozherelkov S.V., Sedov A.M. Phosphorilated polyprenols as universal agents of viral reproduction supression. Biol. Bull. Rev. 2022; 12(6): 609–24. https://doi.org/10.1134/S207908642206007X</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Ershov F.I., Pronin A.V., Sanin A.V., Narovlyansky A.N. The combination of traditional therapy of genital herpes with immunotherapy: experience of using domestic immunotherapeutic drugs. Uspekhi sovremennoi biologii. 2020; 140(3): 263–77. https://doi.org/10.31857/S0042132420030047 https://elibrary.ru/tuqlhx (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Ершов Ф.И., Пронин А.В., Санин А.В., Наровлянский А.Н. Сочетание традиционной терапии генитального герпеса с иммунотерапией: опыт использования отечественных иммунотерапевтических препаратов. Успехи современной биологии. 2020; 140(3): 263–77. https://doi.org/10.31857/S0042132420030047 https://elibrary.ru/tuqlhx</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Narovlyansky A.N., Pronin A.V., Sanin A.V., Sedov A.M., Ershov F.I., Veselovsky V.V., et al. Isoprenoids: Polyprenols and Polyprenyl Phosphates as Physiologically Important Metabolic Regulators. Nova Science Publishers, INC.; 2018.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Zhou B.X., Li J., Liang X.L., Pan X.P., Hao Y.B., Xie P.F., et al. β-sitosterol ameliorates influenza A virus-induced proinflammatory response and acute lung injury in mice by disrupting the cross-talk between RIG-I and IFN/STAT signaling. Acta Pharmacol. Sin. 2020; 41(9): 1178–96. https://doi.org/10.1038/s41401-020-0403-9</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Khan S.L., Siddiqui F.A. Beta-sitosterol: as immunostimulant, antioxidant and inhibitor of SARS-CoV-2 spike glycoprotein. Arch. Pharmacol. Ther. 2020; 2(1): 12–6. https://doi.org/10.33696/Pharmacol.2.014</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Palmer W.K., Emeson E.E., Johnston T.P. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med. Sci. Sports Exerc. 1997; 29(11): 1416–21. https://doi.org/10.1097/00005768-199711000-00005</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Matrosovich M., Matrosovich T., Garten W., Klenk H.D. New low-viscosity overlay medium for viral plaque assays. Virol. J. 2006; 3: 63. https://doi.org/10.1186/1743-422x-3-63</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Sedova E.S., Stepanova L.A., Lysenko A.A., Shcherbinin D.N., Verkhovskaya L.V., Tsybalova L.M., et al. A study of the immunogenicity and protective properties of recombinant influenza vaccine. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2020; 38(3): 136–44. https://doi.org/10.17116/molgen202038031136 https://elibrary.ru/mmnuvs (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Седова Е.С., Степанова Л.А., Лысенко А.А., Щербинин Д.Н., Верховская Л.В., Цыбалова Л.М. и др. Исследование иммуногенности и протективных свойств рекомбинантной вакцины против гриппа. Молекулярная генетика, микробиология и вирусология. 2020; 38(3): 136–44. https://doi.org/10.17116/molgen202038031136 https://elibrary.ru/mmnuvs</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Kuritz T. Methods and compositions for modulation of innate immunity. Patent US № 0306017; 2009.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Jeong A., Suazo K.F., Wood W.G., Distefano M.D., Li L. Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease. Crit. Rev. Biochem. Mol. Biol. 2018; 53(3): 279–310. https://doi.org/10.1080/10409238.2018.1458070</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Pronin A.V., Narovlyanskii A.N., Deryabin P.G., Deeva A.V., Orlova N.G., Grigor’eva E.A., et al. Antiviral effect of Phosprenyl in case of influenza infection. Veterinariya i kormlenie. 2005; (6): 25. (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Пронин А.В., Наровлянский А.Н., Дерябин П.Г., Деева А.В., Орлова Н.Г., Григорьева Е.А. и др. Противовирусное действие Фоспренила при гриппозной инфекции. Ветеринария и кормление. 2005; (6): 25.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Sanin A.V., Deryabin P.G., Narovlyansky A.N., Pronin A.V., Kozhevnikova T.N. Antiviral activity of Phosprenyl and Gamapren against infection caused by influenza A (H5N1) virus in cell culture. Voprosy virusologii. 2017; 62(4): 168–73. https://doi.org/10.18821/0507-4088-2017-62-4-168-173 https://elibrary.ru/zfpbtj (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Санин А.В., Дерябин П.Г., Наровлянский А.Н., Пронин А.В., Кожевникова Т.Н. Противовирусная активность препаратов Фоспренил и Гамапрен в отношении инфекции, вызванной вирусом гриппа А (H5N1 в культуре клеток. Вопросы вирусологии. 2017; 62(4): 168–73. https://doi.org/10.18821/0507-4088-2017-62-4-168-173 https://elibrary.ru/zfpbtj</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Pronin A.V., Deeva A.V., Orlova N.G., Golovischenko K.A., Golovischenko A.A., Belousova R.V. Anti-influenzal effect of Phosprenyl in experiment and its application with the prophylactic purpose in conditions of a poultry factory. Rossiiskii veterinarnyi zhurnal. Sel’skokhozyaistvennye zhivotnye. 2005; (3): 31–4. https://elibrary.ru/oeedjz (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Пронин А.В., Деева А.В., Орлова Н.Г., Головищенко К.А., Головищенко А.А., Белоусова Р.В. Противогриппозное действие Фоспренила в эксперименте и его применение с профилактической целью в условиях птицефабрики. Российский ветеринарный журнал. Сельскохозяйственные животные. 2005; (3): 31–4. https://elibrary.ru/oeedjz</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><mixed-citation>Santos-Marcos J.A., Perez-Jimenez F., Camargo A. The role of diet and intestinal microbiota in the development of metabolic syndrome. J. Nutr. Biochem. 2019; 70: 1–27. https://doi.org/10.1016/j.jnutbio.2019.03.017</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Bouic P.J., Lamprecht J.H. Plant sterols and sterolins: a review of their immune-modulating properties. Altern. Med. Rev. 1999; 4(3): 170–7.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Liu R., Hao D., Xu W., Li J., Li X., Shen D., et al. β-Sitosterol modulates macrophage polarization and attenuates rheumatoid inflammation in mice. Pharm. Biol. 2019; 57(1): 161–8. https://doi.org/10.1080/13880209.2019.1577461</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Bouic P.J. Sterols and sterolins: new drugs for the immune system? Drug Discov. Today. 2002; 7(14): 775–8. https://doi.org/10.1016/s1359-6446(02)02343-7</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Li H., Zhao X., Wang J., Dong Y., Meng S., Li R., et al. β-sitosterol interacts with pneumolysin to prevent Streptococcus pneumoniae infection. Sci. Rep. 2015; 5: 17668. https://doi.org/10.1038/srep17668</mixed-citation></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Sanin A.V., Ganshina I.V., Sudiyna G.F., Sanina V.Yu., Kozhevnkova T.N., Pronin A.V., et al. Phosphorilated polyprenols – a novel class of compounds with anti-inflammatory and bronchial spasmolytic activity. Infektsiya i immunitet. 2011; 1(4): 355–60. https://doi.org/10.15789/2220-7619-2011-4-355-360 https://elibrary.ru/nxerxt (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Санин А.В., Ганшина И.В., Судьина Г.Ф., Санина В.Ю., Кожевникова Т.Н., Пронин А.В. и др. Фосфорилированные полипренолы – новый класс соединений с противовоспалительной и бронхолитической активностью. Инфекция и иммунитет. 2011; 1(4): 355–60. https://doi.org/10.15789/2220-7619-2011-4-355-360 https://elibrary.ru/nxerxt</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><mixed-citation>Loizou S., Lekakis I., Chrousos G.P., Moutsatsou P. β-Sitosterol exhibits anti-inflammatory activity in human aortic endothelial cells. Mol. Nutr. Food Res. 2010; 54(4): 551–8. https://doi.org/10.1002/mnfr.200900012</mixed-citation></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Sanin A.V., Narovlyansky A.N., Pronin A.V., Kozhevnikova T.N., Sanina V.Yu., Agafonova A.D. Study of Phosprenyl antioxidant activity in various biological test systems. Rossiiskii veterinarnyi zhurnal. 2017; (10): 38–41. https://elibrary.ru/zxxxyl (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Санин А.В., Наровлянский А.Н., Пронин А.В., Кожевникова Т.Н., Санина В.Ю., Агафонова А.Д. Изучение антиоксидантных свойств Фоспренила в различных биологических тест-системах. Российский ветеринарный журнал. 2017; (10): 38–41. https://elibrary.ru/zxxxyl</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><mixed-citation>Parvez M.K., Alam P., Arbab A.H., Al-Dosari M.S., Alhowiriny T.A., Alqasoumi S.I. Analysis of antioxidative and antiviral biomarkers β-amyrin, β-sitosterol, lupeol, ursolic acid in Guiera senegalensis leaves extract by validated HPTLC methods. Saudi Pharm. J. 2018; 26(5): 685–93. https://doi.org/10.1016/j.jsps.2018.02.022</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Johnston T.P. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J. Cardiovasc. Pharmacol. 2004; 43(4): 595–606. https://doi.org/10.1097/00005344-200404000-00016</mixed-citation></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Dyadyk A.I., Kugler T.E., Suliman Y.V., Zborovskyy S.R., Zdykhovskaya I.I. Statin adverse effects: mechanisms, diagnosis, prevention and management. Arkhiv’’ vnutrennei meditsiny. 2018; 8(4): 266–77. https://doi.org/10.20514/22266704-2018-8-4-266-276 https://elibrary.ru/xvaonf (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Дядык А.И., Куглер Т.Е., Сулиман Ю.В., Зборовский С.Р., Здиховская И.И. Побочные эффекты статинов: механизмы развития, диагностика, профилактика и лечение. Архивъ внутренней медицины. 2018; 8(4): 266–77. https://doi.org/10.20514/22266704-2018-8-4-266-276 https://elibrary.ru/xvaonf</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><mixed-citation>Palmer W.K., Emeson E.E., Johnston T.P. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis. 1998; 136(1): 115–23. https://doi.org/10.1016/s0021-9150(97)00193-7</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Wout Z.G., Pec E.A., Maggiore J.A., Williams R.H., Palicharla P., Johnston T.P. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J. Parenter. Sci. Technol. 1992; 46(6): 192–200.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Sasaki J., Otonari T., Sawayama Y., Hata S., Oshima Y., Saikawa T., et al. Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study). J. Atheroscler. Thromb. 2012; 19(5): 485–93. https://doi.org/10.5551/jat.12013</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Matvienko O.A., Lewis D.S., Swanson M., Arndt B., Rainwater D.L., Stewart J., et al. A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am. J. Clin. Nutr. 2002; 76(1): 57–64. https://doi.org/10.1093/ajcn/76.1.57</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Vanstone C.A., Raeini-Sarjaz M., Parsons W.E., Jones P.J. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am. J. Clin. Nutr. 2002; 76(6): 1272–8. https://doi.org/10.1093/ajcn/76.6.1272</mixed-citation></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Perminova O.M., Vol’sky N.N., Kudaeva O.T., Goiman E.V., Kozlov V.A. Dyslipidemia and Th1/Th2 relationship at different stages of chronic “graft-versus-host” reaction. Immunologiya. 2009; 30(6): 341–5. https://elibrary.ru/kzsxjj (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Перминова О.М., Вольский Н.Н., Кудаева О.Т., Гойман Е.В., Козлов В.А. Дислипидемия и Th1/Th2-соотношение на разных этапах развития хронической реакции «трансплантат против хозяина». Иммунология. 2009; 30(6): 341–5. https://elibrary.ru/kzsxjj</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><mixed-citation>Gupta A.K., Savapoulos C.G., Ahuja G., Hatzitolios A.I. Role of phytosterols in lipid-lowering: current perspectives. QJM. 2011; 104(4): 301–8. https://doi.org/10.1093/qjmed/hcr007</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Bergamini E., Bizzarri R., Cavallini G., Cerbai B., Chiellini E., Donati A., et al. Ageing and oxidative stress: a role of dolichol in the antioxidant machinery of cell membranes? J. Alzheimers Dis. 2004; 6(2): 129–35. https://doi.org/10.3233/jad-2004-6204</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Bonnans C., Levy B.D. Lipid mediators as agonists for the resolution of acute lung inflammation and injury. Am. J. Respir. Cell. Mol. Biol. 2007; 36(2): 201–5. https://doi.org/10.1165/rcmb.2006-0269tr</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Poeckel D., Funk C.D. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc. Res. 2010; 86(2): 243–53. https://doi.org/10.1093/cvr/cvq016</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Singh G., Gupta P., Rawat P., Puri A., Bhatia G., Maurya R. Antidyslipidemic activity of polyprenol from Coccinia grandis in high-fat diet-fed hamster model. Phytomedicine. 2007; 14(12): 792–8. https://doi.org/10.1016/j.phymed.2007.06.008</mixed-citation></ref></ref-list></back></article>
